Topics

Alexion, Stealth announce agreement for option to co-develop and commercialise late-stage therapy for mitochondrial diseases

05:31 EDT 11 Oct 2019 | Pharmaceutical Business Review

Currently being evaluated in a Phase 3 study in people with primary mitochondrial myopathy (PMM) – a genetic mitochondrial disease – elamipretide is a novel, potential first-in-class therapy

The post Alexion, Stealth announce agreement for option to co-develop and commercialise late-stage therapy for mitochondrial diseases appeared first on Pharmaceutical Business review.

Original Article: Alexion, Stealth announce agreement for option to co-develop and commercialise late-stage therapy for mitochondrial diseases

NEXT ARTICLE

More From BioPortfolio on "Alexion, Stealth announce agreement for option to co-develop and commercialise late-stage therapy for mitochondrial diseases"

Quick Search